- Home
- MCI vs AVTX Comparison
MCI vs AVTX Comparison
Compare MCI & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MCI | AVTX |
|---|---|---|
| Founded | 1971 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 410.7M | 339.9M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | MCI | AVTX |
|---|---|---|
| Price | $19.63 | $13.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $32.57 |
| AVG Volume (30 Days) | 19.3K | ★ 592.2K |
| Earning Date | 01-01-0001 | 03-23-2026 |
| Dividend Yield | ★ 8.46% | N/A |
| EPS Growth | N/A | ★ 72.07 |
| EPS | ★ 1.82 | N/A |
| Revenue | N/A | ★ $27,813,137.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.62 | ★ N/A |
| Revenue Growth | N/A | ★ 2312.27 |
| 52 Week Low | $18.00 | $3.39 |
| 52 Week High | $23.79 | $20.72 |
Technical Indicators
Market Signals| Indicator | MCI | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.43 | 33.74 |
| Support Level | $19.31 | $8.87 |
| Resistance Level | $21.19 | $16.40 |
| Average True Range (ATR) | 0.40 | 1.07 |
| MACD | -0.04 | -0.45 |
| Stochastic Oscillator | 33.42 | 6.70 |
Price Performance
Historical ComparisonAbout MCI Barings Corporate Investors
Barings Corporate Investors is a closed-end management investment company. Its investment objective is to maintain a portfolio of securities providing a current yield and an opportunity for capital gains. The Trust's principal investments are privately placed, below-investment grade, long-term debt obligations, including bank loans and mezzanine debt instruments. The Trust typically purchases these investments, which are not publicly tradable, directly from their issuers in private placement transactions, and the investments are typically made to small or middle market companies.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).